Chargement en cours...

Preclinical and Clinical Experience with Dasatinib in Philadelphia Chromosome-Negative Leukemias and Myeloid Disorders

Recent advances in the molecular characterization of Philadelphia chromosome-negative (Ph−) leukemias and related myeloid disorders have provided a clear rationale for investigating novel targeted therapies. Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL, platelet-derived gro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Res
Auteur principal: Verstovsek, Srdan
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428150/
https://ncbi.nlm.nih.gov/pubmed/19013641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.10.001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!